ACLY and neoplasm: As reductions in ACLY in clinical datasets are also associated with lower tumour burden and increased B cell infiltration, further studies investigating whether pharmacological inhibition of ACLY also increases immunosurveillance and reduces tumour burden in clinical populations will be important.